Home / Health / Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
5 Jun
Summary
- Vafseo, an anemia treatment for kidney disease patients, gained significant prescriber and patient traction.
- Physician prescribers for Vafseo increased by 28%, reaching 1,028, indicating wider adoption.
- The drug saw a 60% quarter-over-quarter rise in patient uptake, with March showing the largest growth.
Akebia Therapeutics is seeing positive momentum with its anemia treatment, Vafseo, approved for patients with chronic kidney disease on dialysis. The company reported substantial early uptake, with the number of prescribing physicians growing by 28% to 1,028 as of early 2026. This expansion reflects a broader prescriber base, extending beyond initial partners to include various clinic groups.
Patient numbers on Vafseo therapy surged by 60% from the first quarter of 2026, with a notable acceleration in March. The company is also encouraged by improved refill rates, reaching 85-90% with three-times-weekly (TIW) dosing, a significant improvement over daily administration. While DaVita, a major potential partner, is proceeding cautiously with TIW protocols, Akebia expects their adoption to be a key driver in the latter half of 2026.
